
BriaCell Therapeutics Corp (NASDAQ:BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer.
Bria-IMT is a cell-based immunotherapy designed to selectively destroy tumor cells without harming the normal cells.